Business Wire8d
Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obe…
Laekna, Inc. (2105.HK) (“Laekna”), a global biotech company focused on novel drug development for metabolic and cancer ...
Eli Lilly in pact with Chinese biotech for novel weight loss therapy
Eli Lilly (LLY) partners with Laekna Therapeutics to develop an obesity therapy that avoids muscle loss. Read more here.
BioSpace7d
Lilly Partners With Chinese Biotech to Advance Muscle-Sparing Obesity Treatment
Lilly will provide the funding and expertise to advance Laekna’s LAE102, a first-in-class monoclonal antibody targeting the ...
China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug
Eli Lilly and Hong Kong-listed Laekna will collaborate to develop an experimental obesity drug that aims to help patients ...
阿思達克財經網1d
LAEKNA-B Places Shrs at 15%+ Discount to Raise $230M Net Proceeds
The net proceeds from the Placing are expected to be fully utilized by December 31, 2026 and will be used for accelerating ...
The Pharma Letter7d
Lilly and Laekna team up on novel obesity drugs
Eli Lilly has partnered with Laekna to advance LAE102, an antibody targeting the ActRIIA receptor, for obesity and muscle ...
Eli Lilly and China-based biotech Laekna team on obesity drug
Earlier on Wednesday, Laekna, “a global biotech company focused on novel drug development for metabolic and cancer diseases,” accoding to its ...
Laekna Partners with Eli Lilly on Obesity Drug Development
Laekna, Inc. (HK:2105) has released an update.Don't Miss out on Research Tools:Discover the latest stocks recommended by top Wall Street ...
阿思達克財經網8d
LAEKNA-B Last Slumps 7%+ after Announcing Shr Placing on 48% Rally Ytd
The placing is expected to raise net proceeds of about $230 million, which are expected to be fully utilized by December 31, ...
Nasdaq8d
Eli Lilly and China-based biotech Laekna team on obesity drug
LAE102 has been shown to both increase lean mass and decrease fat mass in pre-clinical models. If successful, LAE102 could, in combination with a GLP1R agonist, further reduce fat mass and ...